Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.01
-0.01 (-40.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-178819.00 · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$576175
P/E
N/A
•EV/EBITDA
N/A
•ROE
43.3%
↑Gross Margin
85.5%
↑Debt/Equity
-0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-21.1%
FCF CAGR
—
FCF margin
-112.6%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $67887.0 · net income $-631254.0 · FCF $-76437.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $67887.00 | $67887.00 | $113215.00 | $61934.00 | $138154.00 |
| Net Income | $-631254.00 | $-631254.00 | $-456197.00 | $-813149.00 | $-794052.00 |
| EBITDA | $-580897.00 | $-580897.00 | $-404148.00 | $-778829.00 | $-786733.00 |
| EPS | — | — | -0.01 | -0.03 | -0.03 |
| Gross Margin | 85.5% | 85.5% | 75.7% | 87.4% | 97.8% |
| Operating Margin | -854.2% | -854.2% | -423.1% | -1122.4% | -573.5% |
| Net Margin | -929.9% | -929.9% | -402.9% | -1312.9% | -574.8% |
| Balance Sheet | |||||
| Debt/Equity | -0.19 | -0.19 | -0.25 | -0.30 | -0.50 |
| Current Ratio | 0.03 | 0.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-76437.00 | $-76437.00 | $-178819.00 | $-336023.00 | $-670803.00 |
| Returns | |||||
| ROE | 43.3% | 43.3% | 41.8% | 124.7% | 957.2% |
| Growth & Yield | |||||
| Revenue Growth | -40.0% | -40.0% | 82.8% | -55.2% | — |
| EPS Growth | — | — | 66.7% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → n/d
Residual
-50.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.